Session Details
[1T07]Biology of Diseases 02
Wed. Nov 6, 2024 11:05 AM - 12:35 PM JST
Wed. Nov 6, 2024 2:05 AM - 3:35 AM UTC
Wed. Nov 6, 2024 2:05 AM - 3:35 AM UTC
Room7(G301)
Organizers: Jun Yasuda(Miyagi Cancer Center), Toshiro Moroishi(Kumamoto University)
[1T07-01]Zinc and its transporter ZIP10 are key mediators of the anti-cancer effects of tamoxifen in breast cancer
○Manami Sakitani, Tomoka Takatani-Nakase (Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University)
キーテクノロジー:乳がん治療
[1T07-02]O-glycosylation of IRE1 by GalNAc transferase as a novel therapeutic target sustained unfolded protein response (UPR) activation in breast cancer
○Keiji Uchiyama1,2, Tetsuro Yoshimaru1,2, Yosuke Matsushita1,2, Yauso Miyoshi3, Mitsunori Sasa4, Toyomasa Katagiri1,2 (1.National Institute of Biomedical Innovation, Health and Nutrition, 2.Division of Genome Medicine, Institute of Advanced Medical Sciences, Tokushima University, 3.Hyogo Medical University, 4.Tokushima Breast Care Clinic)
キーテクノロジー:グライコプロテオミクス
[1T07-03]Arginine methylation sustains de novo fatty acid synthesis to drive chemoresistance in triple-negative breast cancer.
○Takehiro Yamamoto1, Kiyotaka Oshikawa2, Tetsu Hayashida3, Yohei Masugi4, Mai Itoh1,5, Takako Hishiki1, Naoharu Takano6, Masaki Matsumoto2, Makoto Suematsu1,5 (1.Dept. of Biochem., Sch. of Med., Keio Univ., 2.Dept. of Omics and Systems Biol., Grad. Sch. of Med. and Dent. Sci., Niigata Univ., 3.Dept. of Surg., Sch. of Med., Keio Univ., 4.Dept. of Pathol., Sch. of Med., Keio Univ., 5.Dept. of Biochem., Sch. of Med., Tokyo Medical. Univ., 6.Central institute of experimental medicine)
キーテクノロジー:メタボローム
[1T07-04]Suppression of USP1 expression inhibits cell proliferation in malignant mesotheliomas harboring BAP1 mutation
○Koya Suzuki1,2,3, Kirara Kobayashi1, Takashi Miida4, Hiroshi Murakami5, Yoshitaka Sekido6, Yuko Murakami-Tonami1,2 (1.Mol. Cancer Genet. Lab., Tokyo Univ. Tech. Grad Sch. Bionics, 2.Adv. Comp. Res. Org., Teikyo Univ., 3.Dept. Biochem., Juntendo Univ. Grad. Sch. Med., 4.Fac. Med. Sci., Juntendo Univ., 5.Dept. Biol. Sci., Fac. Sci. Eng., Chuo Univ., 6.Div. Cancer. Biol., Aichi Cancer Ctr. Res. Inst.)
キーテクノロジー:shRNAレンチウイルス
[1T07-05]Development of a new treatment method for hematopoietic tumors targeting deubiquitinating enzyme USP14
○Nami Kurozumi (Kawasaki University of Medical Welfare)
キーテクノロジー:Western Blotting
[1T07-06]PD-1 interactome analysis during nivolumab and dostarlimab response by AirID.
○Haruka Higashiyama1, Kohdai Yamada1, Kohei Nishino2, Atsushi Hijikata3, Hidetaka Kosako2, Tatsuya Sawasaki1 (1.Proteo-Science Center (PROS), Ehime Univ, 2.Fujii Memorial Institute of Advanced Medical Science, Tokushima Univ, 3.Tokyo University of Pharmacy and Life Sciences)
キーテクノロジー:近位依存性ビオチン標識酵素
[1T07-07]Regulation of the interaction of BCR-ABL with VDAC1 can function as a novel therapeutic strategy against CML.
○Yuta Okuda1, Miho Takahashi1, Aoi Ikegami1, Norihito Shibata2, Mikihiko Naito3, Kiyotaka Nishikawa1 (1.Molecular Life Sciences Laboratory, Faculty of Life and Medical Sciences, Doshisha University, 2.Division of Biochemistry, National Institute of Health Sciences, 3.Laboratory of Targeted Protein Degradation, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
キーテクノロジー:BioID法
[1T07-08]Vulnerability of liver cancer cells by cancer-specific aberrant DNA methylation
○Karen Minowa1, Miho Seki1, Yui Nagai2, Satoshi Yamashita1,2 (1.Maebashi Institute of Technology, Graduate School of Engineering, Department of Biotechnology, 2.Maebashi Institute of Technology, Faculty of Engineering, Department of Biotechnology)
キーテクノロジー:Infinium Methylation BeadChip
[1T07-09]Normalization of Tumor Vasculature and Anti-Tumor Effects by Stable Expression of Down Syndrome-Related Transcription Factor ERG
○Hinako Miki, Syunsuke Kamei, Kanako Arata, Shintaro Funasaki, Takashi Minami (Division of Molecular and Vascular Biology, Institute of Resource Development and Analysis, Kumamoto University)
キーテクノロジー:内皮特異的 Erg 誘導モデル
[1T07-10]Development of a novel peptide-based inhibitory compound against EML4-ALK by targeting the substrate binding domain of ALK
○Yifan Shi1, Miho Takahashi1, Hiroyuki Hara1, Norihito Shibata2, Mikihiko Naito3, Atsuko Deguchi4,5, Yoshiro Maru5, Kiyotaka Nishikawa1 (1.molecular life/Preventive Medicine Labratory, Faculty of Life and Medical Sciences, Doshisha University, 2.National institute of Health Sciences, Division of biochemistry, 3.Laboratory of Targeted Protein Degradation, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 4.Institute of Advanced Biomedical Engineering and Scicense, Tokyo Women's Medical University, 5.Department of Pharmacology,Tokyo Women's Medical University)
キーテクノロジー:多価型ペプチドライブラリー法